GT Molecular, Inc.

GT Molecular, Inc., doing business as GT Molecular LLC, is a minority-owned, self-certified small disadvantaged business specializing in advanced molecular diagnostics and surveillance technologies. The company focuses on providing digital PCR-based assay development, optimization, and validation services to support public health initiatives, particularly in the areas of wastewater surveillance for pathogens and antimicrobial resistance. GT Molecular has positioned itself as a key player in the development of multi-pathogen assay panels compatible with various digital PCR platforms, offering crucial services to federal agencies engaged in disease monitoring and control efforts.

As a prime contractor, GT Molecular has been awarded significant federal contracts by the Centers for Disease Control and Prevention (CDC) to support the National Wastewater Surveillance System (NWSS). In September 2024, the company secured a $1,665,445 firm-fixed-price contract, set aside for small businesses, to develop, optimize, and validate a portfolio of sensitive and robust molecular testing assays for multiple pathogens, antimicrobial resistance, and vector targets in wastewater. This contract includes a 12-month base period with four 12-month option periods. Previously, in September 2022, GT Molecular was awarded a $297,003.74 sole-source purchase order to develop a multi-pathogen, digital PCR assay panel compatible with both Qiagen Qiacuity and BioRad QX digital PCR platforms. The company has also provided analytical services as a subcontractor to Eastern Research Group Inc., supporting field sampling activities under a contract with an unspecified federal agency. These contracts demonstrate GT Molecular's expertise in developing specialized molecular testing solutions for federal public health surveillance programs.

In the realm of federal grants, GT Molecular has been involved in innovative research aimed at improving influenza vaccines through wastewater-based macro-scale strain surveillance. In February 2022, the company received a project grant (R43AI167462) from the National Institute of Allergy and Infectious Diseases to develop a novel approach for monitoring influenza and SARS-CoV-2 in community wastewater. This research project, scheduled to run until July 2022, focused on expanding GT Molecular's existing SARS-CoV-2 wastewater monitoring capabilities to include influenza prevalence monitoring and genomic characterization of circulating strains. The goal was to provide a more comprehensive dataset for international surveillance programs to use in their yearly strain inclusion decision-making for vaccine development, potentially improving vaccine efficacy for both influenza and SARS-CoV-2. This grant work showcases GT Molecular's commitment to advancing public health through innovative molecular surveillance techniques and its ability to contribute to cutting-edge research in viral monitoring and vaccine development.

GT Molecular was created to develop new molecular detection technology for cancer research and harmful pathogen detection. The company brings deep experience in molecular genetics, assay technology development, and clinical medicine. Since the beginning of the pandemic, GT Molecular has focused these powerful tools on the detection of SARS-CoV-2 in wastewater to support communities around the country with their monitoring programs.